Head & Neck Cancer
True or False: Cetuximab, a novel dosing regimen recently approved by the FDA, can be dosed alone or in combination with chemotherapy for patients with either colorectal or head and neck cancer.
Long-term results from the ATTRACTION-3 trial show nivolumab improves survival over chemotherapy for patients with advanced esophageal squamous cell carcinoma.
The FDA has approved pralsetinib for the treatment of adult and pediatric patients with RET-mutated thyroid cancer.
Findings from a cohort study suggest that patients with HNSCC who take NSAIDs during chemoradiation may achieve an OS advantage.
True or False: Recent findings suggest that lenvatinib is a potential treatment option for patients with previously treated advanced or metastatic thymic carcinoma.
Study findings show that combining pembrolizumab with weekly cisplatin-based chemoradiotherapy is safe for patients with locally advanced HNSCC.
Lenvatinib demonstrated activity and manageable safety in patients with advanced thymic carcinoma, study findings show.
In a study of patients with relapsed or refractory neuroblastoma, combo therapy with irinotecan, temozolomide, dintuximab, and GM-CSF yielded significant antitumor activity.